제산제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Antacids Market size is expected to reach USD 13.47 Billion in 2034 from USD 8.33 Billion (2025) growing at a CAGR of 5.48% during 2026-2034.

The Global Antacids Market is growing steadily due to the rising prevalence of acid reflux, heartburn, and indigestion worldwide. Changing dietary habits, increased consumption of spicy and processed foods, and stressful lifestyles are key factors contributing to digestive issues. Over-the-counter availability and easy accessibility of antacids make them a preferred choice for quick relief, supporting consistent market demand.

The expansion of retail pharmacies and online distribution channels is further driving growth. Pharmaceutical companies are introducing flavored and fast-acting formulations to improve consumer experience. Additionally, growing awareness about gastrointestinal health and self-medication trends in developing countries are boosting sales. The increasing geriatric population, which is more prone to digestive disorders, also contributes to steady demand.

In the future, the market is expected to benefit from product innovation and combination therapies that provide enhanced effectiveness. Rising healthcare awareness and expanding healthcare infrastructure in emerging economies will create new opportunities. As consumers continue to seek convenient and affordable solutions for digestive discomfort, the global antacids market is projected to maintain stable growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Sodium Antacids
• Calcium Antacids
• Magnesium Antacids
• Aluminium Antacids
• Others

By Indication

• Gastroesophageal Reflux Disease
• Heartburn
• Indigestion
• Others

By Dosage Form

• Tablets
• Liquid
• Others

By Route of Administration

• Oral
• Others

By End Users

• Hospitals
• Homecare
• Speciality Centres
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

COMPANIES PROFILED

• Pfizer Inc, F HoffmannLa Roche Ltd, Mylan NV, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Lupin, Cipla Inc, Aurobindo Pharma, Procter Gamble
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTACIDS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Sodium Antacids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Calcium Antacids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Magnesium Antacids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Aluminium Antacids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTACIDS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Gastroesophageal Reflux Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Heartburn Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Indigestion Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTACIDS MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Dosage Form
• 6.2. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Liquid Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTACIDS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTACIDS MARKET: BY END USERS 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End Users
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Speciality Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTACIDS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Distribution Channel
• 9.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL ANTACIDS MARKET: BY REGION 2022-2034(USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Type
  • 10.2.2 By Indication
  • 10.2.3 By Dosage Form
  • 10.2.4 By Route Of Administration
  • 10.2.5 By End Users
  • 10.2.6 By Distribution Channel
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Type
  • 10.3.2 By Indication
  • 10.3.3 By Dosage Form
  • 10.3.4 By Route Of Administration
  • 10.3.5 By End Users
  • 10.3.6 By Distribution Channel
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Type
  • 10.4.2 By Indication
  • 10.4.3 By Dosage Form
  • 10.4.4 By Route Of Administration
  • 10.4.5 By End Users
  • 10.4.6 By Distribution Channel
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Type
  • 10.5.2 By Indication
  • 10.5.3 By Dosage Form
  • 10.5.4 By Route Of Administration
  • 10.5.5 By End Users
  • 10.5.6 By Distribution Channel
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 South East Asia
  • 10.5.12 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Type
  • 10.6.2 By Indication
  • 10.6.3 By Dosage Form
  • 10.6.4 By Route Of Administration
  • 10.6.5 By End Users
  • 10.6.6 By Distribution Channel
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL ANTACIDS INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Pfizer Inc
  • 12.2.2 F. Hoffmann-La Roche Ltd
  • 12.2.3 Mylan N.V
  • 12.2.4 Fresenius Kabi AG
  • 12.2.5 Hikma Pharmaceuticals PLC
  • 12.2.6 Novartis AG
  • 12.2.7 Teva Pharmaceutical Industries Ltd
  • 12.2.8 Bristol Myers Squibb Company
  • 12.2.9 GSK Plc
  • 12.2.10 Bayer AG
  • 12.2.11 Sun Pharmaceutical Industries Ltd
  • 12.2.12 Lupin
  • 12.2.13 Cipla Inc
  • 12.2.14 Aurobindo Pharma
  • 12.2.15 Procter & Gamble